Related Experiment Videos
[Prediction of the prognosis in multiple myeloma--clinical studies on prognostic factors using multivariative
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology
|October 1, 1985
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Hereditary Red Cell Membrane Disorders in Japan: Their Genotypic and Phenotypic Features in 1014 Cases Studied.
Hematology (Amsterdam, Netherlands)·2016
[(18) F]-Fluorodeoxy-d-glucose uptake-positive seborrhoeic keratosis on positron emission tomography may result from high expression of glucose transporter.
The British journal of dermatology·2016
Antitumor efficacy of oncolytic herpes simplex virus adsorbed onto antigen-specific lymphocytes.
Cancer gene therapy·2012
[Treatment landscape of mature NK/T-cell lymphomas: treatment outcomes in Japan and future prospects].
[Rinsho ketsueki] The Japanese journal of clinical hematology·2026
[Prophylactic or pre-emptive therapy with azacitidine or FLT3 inhibitor after allogeneic hematopoietic stem cell transplantation for AML and MDS].
[Rinsho ketsueki] The Japanese journal of clinical hematology·2026
[Prophylactic use of tyrosine kinase inhibitors after allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia].
[Rinsho ketsueki] The Japanese journal of clinical hematology·2026
[Development of universal off-the-shelf T cell therapies derived from ES/iPS cells for leukemia and COVID-19].
[Rinsho ketsueki] The Japanese journal of clinical hematology·2026
[Predictors of treatment-free remission (TFR) and second TFR attempts in chronic myeloid leukemia].
[Rinsho ketsueki] The Japanese journal of clinical hematology·2026
[Complement-coagulation crosstalk in immunothrombosis].
[Rinsho ketsueki] The Japanese journal of clinical hematology·2026
Hypoxia-Induced Expression of miR-424, miR-155, CD47, and PD-L1 in a Gastric Cancer Cell Line (MKN-45).
Iranian biomedical journal·2026
Long-term safety of first-line osimertinib plus platinum-pemetrexed in EGFR-mutated advanced NSCLC: FLAURA2.
Lung cancer (Amsterdam, Netherlands)·2026